“These tumours are ultra rare, and it is simply not feasible to run a clinical trial involving hundreds of patients,” says Vivien Wong, executive vice president of R&D at Progenics ...
Melinta Therapeutics, LLC ("Melinta"), a commercial-stage company providing innovative therapies for acute and ...
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE:BMR) announced today that it has entered into a new ten-year lease with Progenics ...
Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with ...
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of ...
His non-academic experiences include working for Goldman, Sachs & Co., being the President of Progenics Pharmaceuticals, Inc. a start-up biotechnology company, and being the director of economics for ...
Molecular Insight was subsequently acquired by Progenics in 2013, who oversaw the completion of clinical testing and development of the drug. Unlike LSA-MIBG, HSA-MIBG was subjected to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback